Liang H, Wang M. MET oncogene in non-small cell lung cancer: mechanism of MET dysregulation and agents targeting the HGF/c-Met axis. Onco Targets Ther. 2020;13:2491–510.

CAS  PubMed  PubMed Central  Google Scholar 

Recondo G, Che J, Janne PA, et al. Targeting MET dysregulation in cancer. Cancer Discov. 2020;10(7):922–34.

CAS  PubMed  PubMed Central  Google Scholar 

Gherardi E, Birchmeier W, Birchmeier C, et al. Targeting MET in cancer: rationale and progress. Nat Rev Cancer. 2012;12(2):89–103.

CAS  PubMed  Google Scholar 

AbbVie. AbbVie announces U.S. FDA granted Breakthrough Therapy Designation (BTD) to telisotuzumab vedotin (Teliso-V) for previously treated non-small cell lung cancer [media release]. 4 Jan 2022. http://www.abbvie.com.

AbbVie. AbbVie submits biologics license application to the FDA for telisotuzumab vedotin (Teliso-V) in previously treated non-small cell lung cancer [media release]. 27 Sep 2024. http://www.abbvie.com.

AbbVie Inc. EMRELISTM (telisotuzumab vedotin-tllv) for injection, for intravenous use: US prescribing information. 2025. https://www.rxabbvie.com/pdf/emrelis_pi.pdf. Accessed 25 Jun 2025.

US Food & Drug Administration. FDA grants accelerated approval to telisotuzumab vedotin-tllv for NSCLC with high c-Met protein overexpression [media release]. 14 May 2025. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-telisotuzumab-vedotin-tllv-nsclc-high-c-met-protein-overexpression.

AbbVie, Bristol-Myers Squibb Company. AbbVie and Bristol-Myers Squibb announce clinical research collaboration to evaluate a therapeutic regimen in advanced solid tumors [media release]. 22 Sep 2017. http://www.abbvie.com.

Wang J, Anderson MG, Oleksijew A, et al. ABBV-399, a c-Met antibody-drug conjugate that targets both MET-amplified and c-Met-overexpressing tumors, irrespective of MET pathway dependence. Clin Cancer Res. 2017;23(4):992–1000.

CAS  PubMed  Google Scholar 

Camidge DR, Barlesi F, Goldman JW, et al. Phase Ib study of telisotuzumab vedotin in combination with erlotinib in patients with c-Met protein-expressing non-small-cell lung cancer. J Clin Oncol. 2023;41(5):1105–15.

CAS  PubMed  Google Scholar 

Camidge DR, Morgensztern D, Heist RS, et al. Phase I study of 2- or 3-week dosing of telisotuzumab vedotin, an antibody-drug conjugate targeting c-Met, monotherapy in patients with advanced non-small cell lung carcinoma. Clin Cancer Res. 2021;27(21):5781–92.

CAS  PubMed  PubMed Central  Google Scholar 

Horinouchi H, Cho BC, Camidge DR, et al. Results from a phase Ib study of telisotuzumab vedotin in combination with osimertinib in patients with c-Met protein-overexpressing, EGFR-mutated locally advanced/metastatic non-small-cell lung cancer (NSCLC) after progression on prior osimertinib. Ann Oncol. 2025;36(5):583–91.

CAS  PubMed  Google Scholar 

Strickler JH, Weekes CD, Nemunaitis J, et al. First-in-human phase I, dose-escalation and -expansion study of telisotuzumab vedotin, an antibody-drug conjugate targeting c-Met, in patients with advanced solid tumors. J Clin Oncol. 2018;36(33):3298–306.

CAS  PubMed  Google Scholar 

Camidge DR, Barlesi F, Goldman JW, et al. A phase 1b study of telisotuzumab vedotin in combination with nivolumab in patients with NSCLC. JTO Clin Res Rep. 2022. https://doi.org/10.1016/j.jtocrr.2021.100262.

Article  PubMed  PubMed Central  Google Scholar 

Fujiwara Y, Kenmotsu H, Yamamoto N, et al. Phase 1 study of telisotuzumab vedotin in Japanese patients with advanced solid tumors. Cancer Med. 2021;10(7):2350–8.

CAS  PubMed  PubMed Central  Google Scholar 

Camidge DR, Bar J, Horinouchi H, et al. Telisotuzumab vedotin monotherapy in patients with previously treated c-Met protein-overexpressing advanced nonsquamous EGFR-wildtype non-small cell lung cancer in the phase II LUMINOSITY trial. J Clin Oncol. 2024;42(25):3000–11.

CAS  PubMed  Google Scholar 

Roche. Roche receives FDA approval for the VENTANA MET (SP44) RxDx Assay as the first companion diagnostic to identify non-squamous non-small cell lung cancer patients eligible for treatment with Emrelis [media release]. 14 May 2025. http://www.roche.com.

Lu S, Goldman J, Tanizaki J, et al. A phase 3 global study of telisotuzumab vedotin versus docetaxel in previously treated patients with c-Met 0verexpressing, EGFR wildtype, locally advanced/metastatic nonsquamous NSCLC (TeliMET NSCLC-01) [abstract no. TPS8656]. J Clin Oncol. 2024;42(16 Suppl).

Zer A, Ratajczak C, Adamu H, et al. TeliMET NSCLC-04: a phase 2, open-label, randomized, global study of 2 telisotuzumab vedotin regimens in patients with previously treated c-Met protein–overexpressing, locally advanced/metastatic non-squamous EGFR wildtype non-small cell lung cancer [abstract no. TPS8658]. J Clin Oncol. 2025;42(16 Suppl).